Skip to content

PHYSIOPATHOLOGY OF NONALCOHOLIC HEPATIC STEATOSIS AND EFFICACY OF SILYMARIN IN THE THERAPY OF NONALCOHOLIC HEPATIC STEATOSIS

PHYSIOPATHOLOGY OF NONALCOHOLIC HEPATIC STEATOSIS AND EFFICACY OF SILYMARIN IN THE THERAPY OF NONALCOHOLIC HEPATIC STEATOSIS

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-002966-12-IT
Enrollment
100
Registered
2005-11-04
Start date
2005-03-23
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic hepatic steatosis MedDRA version: 6.1 Level: PT Classification code 10019708

Interventions

Trade Name: LEGALON-140*30 CPR RIV.140MG Pharmaceutical Form: Coated tablet INN or Proposed INN: VARI CAS Number: 65666-07-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration

Sponsors

TRASTEC
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026